ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Fortress Biotech Announces Initiation of Phase 3 Studies of CAEL-101 in AL Amyloidosis
September 21, 2020Fortress Biotech announced Caelum Biosciences, in collaboration with Alexion Pharmaceuticals, has initiated the Cardiac Amyloid Reaching for Extended Survival (CARES) Phase 3 clinical program to evaluate CAEL-101 ... -
Fortress Biotech Announces EMA Orphan Drug Designation for Menkes Disease Treatment
August 11, 2020Fortress Biotech announced the European Medicines Agency (EMA) Committee for Orphan Medicinal Products issued a positive opinion on Cyprium Therapeutics’ (Cyprium) application for Orphan Drug Designation for Copper Histidinate ... -
Fortress Biotech Forms New Subsidiary
January 09, 2017Caelum Biosciences together with Columbia Univ. to develop novel treatment for AL amyloidosis
Pharma Sources Insight January 2025
